Ge Long Hui·2026-01-30 11:41Core Viewpoint - Rongchang Biologics (09995.HK) is expected to achieve significant revenue growth in 2025, with projected operating income of approximately RMB 3.25 billion, representing an increase of about RMB 1.533 billion or 89% year-on-year [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately RMB 716 million for 2025, marking a turnaround from a loss to profit compared to the previous year [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is approximately RMB 78.5 million, also indicating a turnaround from a loss to profit year-on-year [1][2] Group 2: Business Drivers - The core products, Taitasip and Vidisitimab, are expected to see rapid growth in domestic sales, serving as the main growth engine for the company's performance in 2025 [1] - The company has successfully established a significant partnership, granting Vor Biopharma Inc. exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [1] - The company has reduced unit production costs through management optimization and production process iteration, which has improved product gross margins, while also significantly decreasing the sales expense ratio [1]